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Abstract
Pulmonary embolism response teams (PERTs) have emerged as a multidisciplinary,
multispecialty team of experts in the care of highly complex symptomatic acute pulmonary embolism (PE), with a centralized unique activation process, providing rapid
multimodality assessment and risk stratification, formulating the best individualized
diagnostic and therapeutic approach, streamlining the care in challenging clinical case
scenarios (e.g., intermediate–high risk and high-risk PE), and facilitating the implementation of the recommended therapeutic strategies on time. PERTs are currently
changing how complex acute PE cases are approached. The structure, organization,
and function of a given PERT may vary from hospital to hospital, depending on local
expertise, specific resources, and infrastructure for a given academic hospital center.
Current emerging data demonstrate the value of PERTs in improving time to PE diagnosis; shorter time to initiation of anticoagulation reducing hospital length of stay;
increasing use of advanced therapies without an increase in bleeding; and in some
reports, decreasing mortality. Importantly, PERTs are positively impacting outcomes
by changing the paradigm of care for acute PE through global adoption by the health-
care community.
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1 | I NTRO D U C TI O N A N D S CO PE O F TH E
PRO B LE M

specialists leveraging local knowledge and technical expertise in
acute PE.6,7 One of the main goals of PERTs is to use this multidisciplinary decision-making process to determine the best therapeutic plan for each patient. It is important to emphasize that the

Acute pulmonary embolism (PE) represents the third most common

structure of PERTs will vary from hospital to hospital, and there is

cause of cardiovascular death globally, behind myocardial infarction

no defined or specific number of team members. PERTs come in

and stroke. Accounting for approximately 100 000 deaths across the

multiple “shapes and sizes.” In some hospitals, there may be two

United States each year, PE is associated with significant morbidity

to four members within a given PERT, whereas in more prominent

1

and mortality. Unlike other medical problems, the management of

academic centers, that number may range between six and twelve

acute PE does not belong to one specialty. Instead, it can involve

members. However, a PERT leader must orchestrate and moderate

many different medical and surgical specialties. Furthermore, di-

discussion of challenging case scenarios among participants, and

agnosis, risk stratification, triage, and treatment vary depending

ideally, a skilled interventionalist on the team. PERT team members

on hospital resources and the experience and expertise of health-

may include specialists from cardiology, interventional cardiology,

care providers. Currently, there is no standardized, consistent, sys-

pulmonary/critical care medicine, hematology, vascular surgery, vas-

tematic approach in the therapeutic decision-making process for

cular medicine, and interventional radiology with some variability

complex cases of acute PE, particularly for patients suffering from

across hospitals. 2–7 The emergent activation/consultation of a PERT

intermediate–high and high-risk PE. 2

can occur virtually in any section of the hospital, and sometimes

This lack of standards and robust scientific evidence was the

can come from an outside facility. For the latter scenario, a well-

impetus behind the pulmonary embolism response teams (PERT),

structured inter-hospital transfer plan must be carefully executed to

starting in 2012 at the Massachusetts General Hospital (MGH) in

safely transfer a patient without significant clinical deterioration or

3

Boston. Shortly after MGH created and publicized its PERT, other

worsening hemodynamic instability in the process.8,9 PERT provid-

university-based and community-based hospitals built their own in-

ers must obtain pertinent clinical history, imaging, and laboratory

stitutional PERTs. Fortunately, the therapeutic armamentarium for

data as quickly as possible. Subsequently, in a multidisciplinary man-

the treatment of PE has evolved beyond systemic anticoagulation

ner, the PERT team will use this data to make the best therapeutic

alone. It now includes systemic thrombolysis, catheter-directed

decisions on managing complex PE cases. This timing of PERTs may

therapies, surgical pulmonary embolectomy (SPE), and mechani-

vary and depends on the complexity and urgency of the situation.9

cal circulatory support systems like extracorporeal membrane ox-

The PERT model streamlines care in the setting of acute complex

ygenation (ECMO). These therapeutic advances appeared to have

PE cases, facilitating rapid, effective, and efficient multidisciplinary

evolved in parallel with the creation of PERTs, and together have

communication, allowing for fast hospital-specific mobilization of

become tools in treating challenging PE cases. 2,3 In May 2015, the

local resources for a given patient, positively impacting the mor-

PERT Consortium was created, whose purpose is to “serve the gen-

bidity and mortality of this life-threatening condition.6,7 Figure 1

eral public by undertaking activities to advance the status of PE care

illustrates a schematic flow diagram showing the criteria for activa-

and promote research in the treatment of PE” (https://pertconsor

tion, dynamics, organization, functionality, and fundamental roles of

tium.org/about/). Since its inception, the PERT Consortium has more

PERT members during the care of complex acute PE. Table 1 illus-

than 100 hospitals/institutions registered, and it has grown beyond

trates diverse PERTs’ multispecialty members potentially involved in

the United States to include sites in Australia, Brazil, China, Japan, as

the care of acute PE.

well as several countries in Europe (i.e., Spain, Ireland, Poland, and
the Netherlands).4

2 | S TRU C T U R E , FU N C TI O N , A N D
R ATI O N A LE FO R PE RTs

3 | TH E R A PEU TI C TO O L S AVA I L A B LE FO R
PE RTs
Systemic anticoagulation with either subcutaneous low molecular
weight heparin (LMWH) or intravenous (IV) unfractionated heparin

PERTs represent an innovative and effective way to perform early

(UFH) should be initiated as soon as an acute PE is suspected even

and appropriate risk stratification, and a therapeutic approach in a

before confirmation by imaging modalities if suspicion is high and

multidisciplinary fashion. The primary objective is to improve out-

the bleeding risk is considered low or acceptable. Current clinical

comes and survival in challenging patients with complex clinical

practice guidelines from the 2019 acute PE European Society of

scenarios.5 PERT members vary by institution and involve several

Cardiology (ESC)/European Respiratory Society (ERS) and the latest

|
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3

F I G U R E 1 Schematic flow diagram showing the criteria for activation, dynamics, organization, functionality, and fundamental roles of
PERT members during the care of complex acute PE. Adapted from Porres-A guilar et al. 2 CTA, computed tomography angiogram; ECG,
electrocardiogram; PE, pulmonary embolism; PERT, pulmonary embolism response team.

TA B L E 1 Mnemonics of medical and surgical specialties that
may be involved in pulmonary embolism response teams (PERTs)

UFH may be a better option due to its shorter half-life, ability to

Hospitalist/internist or family medicine (primary care team)
• Pulmonary/critical care
• Endovascular specialist (e.g., interventional cardiology and
emergency medicine)
• Radiology (diagnostic and interventional)
• Thrombosis specialist (e.g., hematology, cardiology, or vascular
medicine)
• Surgery (e.g., cardiothoracic and vascular)

mine sulfate. Additionally, if systemic thrombolysis (ST) is strongly

adjust the dose in a short time, and its easy reversibility with protaconsidered, UFH may be the preferred agent.10,11
The use of ST may be considered in high-risk (massive) acute
PE and no absolute contraindications; the ESC/ERS acute PE
2019 guidelines give a Class-I recommendation for the use of ST
in high-risk PE.10 However, ST in patients with intermediate–high
risk PE patients remains controversial and continues to be investi-

Note: Inpatient pharmacists with expertise in antithrombotic therapies,
and specialized thrombosis inpatient nurses could also be part of PERTs;
however, depending on specific needs, and local resources available for
every institution or hospital for a given PERT, members may vary. PERTs
can be inclusive beyond the specialties mentioned above.

gated.13 The PEITHO-3 (NCT04430569) is an ongoing randomized,

PERT consortium statement recommend the use of LMWH as initial

patients. The primary efficacy outcome is the composite of all-cause

therapy for acute PE, particularly for intermediate–low and low-risk

death, hemodynamic collapse, or venous thromboembolism (VTE)

acute PE, and if no immediate interventions are planned to be per-

recurrence within 30 days of randomization.13

10,11

formed.

placebo-controlled, double-blind, multicenter, multinational trial
with long-term follow-up to compare the efficacy and safety of a
reduced-dose systemic IV alteplase regimen with standard heparin
anticoagulation. The study will enroll 659 intermediate–high-risk PE

Support for using LMWH is further demonstrated in a

Catheter-directed therapies (CDT) such as catheter-directed

recent retrospective analysis of 505 patients with acute PE treated

thrombectomy with suction/maceration, aspiration, and/or frag-

with UFH (either bolus + infusion or infusion alone) where more than

mentation with mechanical thrombectomy, and catheter-directed

half of the patients failed to achieve any therapeutic activated par-

thrombolysis with or without ultrasound facilitation are therapeutic

tial thromboplastin time (APTT) level within 24 h of UFH initiation.12

options that may be considered in patients with indications for ad-

If there are concerns for hemorrhagic complications, intravenous

vanced therapies, especially in those with higher hemorrhagic risks

4
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or with absolute or relative contraindications to ST, respectively.14
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PU B LI S H E D O U TCO M E S W ITH PE RTs

Unfortunately, these endovascular percutaneous techniques may
not be available in all hospitals, and their use is contingent upon local

There are more than 100 indexed articles in PubMed/National

expertise and resources.

Library of Medicine/Medline databases about PERTs, reflecting

SPE is recommended for high-risk acute PE if there is an ab-

that this approach is relatively novel and evolving, but an extremely

solute contraindication to ST or if ST and/or CDT has failed. SPE

passionate topic within the world of VTE. The MGH reported their

may also be considered in the setting of intracardiac thrombi in

first observational, descriptive analysis of the initial 30-month ex-

transit.15

perience with PERTs in 2016.19 In that paper, there were 394 PERT

In selected hemodynamically unstable high-risk acute PE pa-

activations, with a sustained increase of 16% every 6 months after

tients, the use of ECMO has shown benefits while waiting for de-

the creation of the team, confirming the rapid adoption of the PERT

finitive intervention. ECMO offers the potential to stabilize severely

model. The most common therapeutic modality recommended by

decompensated acute PE patients with impending right ventricular

the MGH PERT at that time was systemic anticoagulation (69%),

failure, refractory hypoxemia, or cardiac arrest.14 The veno-arterial

followed by CDT (9%) and ST (5%).19 These initial findings were

configuration (VA-ECMO) can be utilized as a bridge to more ad-

provocative and, since then, have sparked numerous additional de-

vanced reperfusion strategies such as CDT, SPE, or as a protoco-

scriptive, retrospective, and comparative analyses by other PERT

lized, stand-alone therapeutic strategy in high-risk PE patients who

institutions. 20,21

are not ideal candidates for advanced reperfusion therapies, and has
16,17

demonstrated a reduction in mortality.

Wright et al. conducted an observational analysis of 137 patients
before PERT implementation between 2014–2015 and 231 patients

Inferior vena cava (IVC) filters should be reserved for patients

after PERT implementation. The primary outcome was 6-month mor-

with acute PE who have contraindications to anticoagulation.18

tality. PERT was associated with a sustained reduction in mortality

Under particular and challenging circumstances, such as in those

through 6 months (6-month mortality rates of 14% post-PERT vs. 24%

with a history of multiple recurrent VTE despite being adequately

pre-PERT, unadjusted hazard ratio [HR] of 0.57, relative risk ratio [RRR]

anticoagulated, IVC filters may also be considered.18 PERTs may be

of 43%, p = .025). Additionally, there was a reduced length of stay fol-

helpful in deciding which patients may benefit from advanced ther-

lowing PERT implementation (9.1 vs. 6.5 days, p = .007), concluding

apies by balancing the paucity of robust studies with technological

that performance of PERTs had a sustained reduction in 6-month mor-

advancements with multiple endovascular devices that could poten-

tality, particularly for patients with high-risk acute PE.22 There were

tially be useful in appropriately selected patients. Figure 2 illustrates

few limitations in this study; as it was observational, there was inher-

PERT indicators for activation and guides potential therapeutic op-

ent risk for biases; the number of patients was significantly higher in

tions for patients with acute complex PE.

the post-PERT implementation; greater use of echocardiography and

F I G U R E 2 PERT indicators for activation and guide for potential therapeutic options in patients with acute complex PE. Adapted and
modified from Rivera-Lebron et al.11 BP, blood pressure; CDT, catheter-directed therapies; CT, computed tomography; PE, pulmonary
embolism; PESI, pulmonary embolism severity index; RV, right ventricle; SPE, surgical pulmonary embolectomy; ST, systemic thrombolysis;
VA-ECMO, veno-arterial extracorporeal membrane oxygenation.
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biomarkers were used compared to pre-PERT performance, identify-

5

CDT (11.3%), ST (5.3%), SPE (2.4%), IVC filter placement (3.7%),

ing more patients with intermediate-risk PE in the post-PERT imple-

and ECMO (0.6%). In-h ospital mortality in the whole study group

mentation; and investigators were not able to adjudicate causes of

was 5.1%. This European study emphasized the significant varia-

death, and differences in complications from acute PE.22

tion in PERTs between institutions, particularly from the organiza-

Carroll et al. performed a retrospective comparative analysis
in pre-PERT and post-PERT eras, evaluating in-hospital acute PE-

tional and operational points of view, with an acceptable mortality
rate overall. 25

related mortality for 3 years pre-PERT and 3-years post-PERT im-

Jerjes-S ánchez et al. created and described their first PERT

plementation. Of the 2042 patients included in the analysis, 165

in Mexico, the PREVENTION team. Such a multidisciplinary team

(14.2%) were associated with PERT activations, there was no differ-

may be activated with acute complex proximal extensive deep vein

ence in PE-related mortality between the two time periods (2.6%

thromboses, with the primary objective to cover the full clinical

pre-PERT implementation vs. 2.9% post-PERT implementation,

spectrum of VTE, providing fast identification and rapid institution

p = .89);23 however, IVC filters utilization decreased in the post-

of best therapies for patients with high-risk features. Ideally within

PERT era (10.7% pre-PERT implementation vs. 6.9% post-PERT im-

the first 60–90 min post-PERT consult activation, the team must

plementation, p = .002).

23

come up with a solid therapeutic recommendation by consensus,

Chaudhury et al. evaluated 769 patients from the Cleveland

mainly if ST or CDT are considered, because time is of essence

Clinic and found that post-PERT implementation patients had lower

for right ventricular ischemia/infarction, thrombus resistance,

rates of major or clinically relevant nonmajor bleeding (17.0% vs.

and limb salvage as well as preventing long-term complications

8.3%, p = .002), shorter time-to-therapeutic systemic anticoagu-

like post-t hrombotic syndrome, chronic thromboembolic disease,

lation (16.3 h vs. 12.6 h, p = .009), as well as decreased use of IVC

chronic thromboembolic pulmonary hypertension, and post-PE

filters (22.2% vs. 16.4%, p = .004). Importantly, there was a signifi-

syndrome. 26

cant decrease in 30-day/inpatient mortality (8.5% vs. 4.7%, p = .03).

In a nationwide survey performed in China, Wang et al. 27 showed

These differences in outcomes were more pronounced in the inter-

that only one fourth of hospitals had a fully functional PERT pro-

mediate and high-risk acute PE subgroups (mortality 10.0% vs. 5.3%,

gram. In contrast, the majority of PERTs were partially operating,

p = .02). 24

and under development, emphasizing the urgent need of further

Araszkiewicz et al. recently described the first Polish PERT

studying PERT outcomes in China. More recently, the Chinese PERT

initiative results in 690 unique PERT activations. Most PERT ac-

Alliance published its first consensus document highlighting PERTs,

tivations were generated in patients with intermediate–high risk

the incorporation of international PERT practice, the promotion of

PE (42.9%), whereas high-r isk PE occurred in 10% of patients.

PERTs, and the standardization of PERT centers. 28 Table 2 summa-

Systemic anticoagulation alone was delivered to 80.3% of patients

rizes studies regarding clinical outcomes and the impact of diverse

and 23.3% of patients received at least one advanced therapy:

PERTs.

TA B L E 2 Studies summarizing clinical
outcomes and impact of diverse PERT
activations

Study

Number of patients

Outcomes

Kabrhel et al.

394 PERT activations

69% of patients received AC CDT in 9%, ST
in 5%

Wright et al. 22

137 pre/post-PERT

↓6 months mortality rate; ↓ LOS

2042 pre/post-PERT

↑ Risk stratification assessment by cardiac
biomarkers and TTE. ↓ IVC filters use. No
difference in mortality

Chaudhury
et al. 24

769 pre/post-PERT

↓ Rate of bleeding; ↓ Time-to-therapeutic AC; ↓
IVC filters; ↓ 30-day mortality

Araszkiewiecz
et al. 25

690 PERT Activations

ST alone in 80.3% of patients 23.3% received
advanced therapy: CDT 11.3%, ST 5.3%
SPE in 2.4% and ECMO in 0.6%

Annabathula
et al.34

530 pre/post-PERT

↓ In-hospital mortality; ↓ LOS; ↓ total cost of
care

Myc et al.35

554 patients

↓ All-c ause mortality. Improved outcomes
compared to patients who did not receive
PERT

19

Carroll et al.

23

Abbreviations: AC, anticoagulation; CDT, catheter-directed therapies; ECMO, extracorporeal
membrane oxygenation; IVC, inferior vena cava; LOS, length of stay; PERT, pulmonary embolism
response team; SPE, surgical pulmonary embolectomy; ST, systemic thrombolysis; TTE,
transthoracic echocardiography.
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5 | RO LE O F PE RTs D U R I N G TH E
COV I D -1 9 PA N D E M I C

to diagnose acute PE, prompt utilization of therapeutic anticoagulation, and reductions in length of stay. Since its inception, the PERT
Consortium has offered guidance on how to improve the care of

It is well known now that contracting the novel coronavirus disease

PE patients, such as treatment of PE patients during COVID and,

2019 (COVID-19) represents a significant hypercoagulable risk factor

more recently, how to treat PE patients in rural settings. The PERT

for VTE development, particularly in hospitalized patients with mod-

Consortium recently developed a position paper on transferring pa-

erate and severe forms of COVID-19. 29 The development of acute

tients from a remote rural-based hospital to a centralized institution

PE/VTE associated with or complicated by COVID-19 represents a

with higher volume and more resources available.8 Furthermore, the

unique and challenging clinical scenario. However, PERT members

PERT Consortium has an ongoing prospective multinational registry,

play an essential role by providing adequate, evidence-based guid-

addressing knowledge gaps around quality of care, achieving excel-

ance and showing the best therapeutic strategies for challenging and

lence and optimal care in complex cases of acute PE, and evaluating

complex cases of COVID-19–associated VTE. Therefore, PERTs must

the efficacy and efficiency of PERTs.

assist and proactively address important aspects of this severe com-

Many other diseases have centers of excellence (COE) which

plication. Recently, a brief perspective and opinion paper by Porres-

have been recently defined as organizational design, personnel, ser-

Aguilar et al.30,31 and a recent PERT consortium informative position

vicescape design, readily available cutting-edge advanced medical

statement document by Rosovsky et al., published in 2020, address

therapies, marketing, and financial impact.35 PERTs already fulfill

this clinical scenario and propose critical points for optimal patient

many of these features, and creating COE may be the next step in

care of complex acute VTE in the setting of COVID-19.

32

We believe

their evolution.36,37

that a team-based approach like PERTs for clinical decision making,

PERTs represent a concept and a continuously evolving process

and coordination of care, have been critical during the pandemic. For

under dynamic changes. There has been widespread adoption of

instance, PERTs can play a role when suspecting acute PE in a com-

PERTs, with increased activation, utilization, and input since their in-

plicated and challenging patient. Multiple national and international

ception almost a decade ago; however, more data in the form of na-

collaborations among clinical researchers, societal clinical practice

tional and international registries and randomized trials are needed to

guidelines, and statement documents have been published to guide

demonstrate a true net clinical benefit of PERTs. In addition, studies

VTE prophylaxis in COVID-19 patients and many have been coau-

are needed to address improving morbidity and mortality in acute PE

thored by PERT leaders, to ultimately improve the care of hospital-

and minimizing major and fatal bleeding complications. The ESC/ERS

ized patients with COVID-19.32,33

acute PE 2019 guidelines on managing intermediate–high and high-
risk acute PE patients currently recommend the potential utilization

6
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of designated PERTs if available as a class II-A recommendation.10
As PERTs continue to evolve rapidly, these dynamic changes may
facilitate the implementation of clinical research, particularly on

Available data suggest that implementing a PERT improves the qual-

how PERTs can impact appropriate utilization of therapeutic tools

ity of life and cost of care, resulting in improved value. This may be

available for a given complex acute PE patient. Areas of interest

due to more timely identification and risk stratification leading to

include exploration and description of the current performance of

earlier interventions and streamlined decision making, leading to

PERTs including major and fatal bleeding events, particularly in pa-

better outcomes and shorter length of stay in the hospital.34 Myc

tients chronically taking oral anticoagulation therapies for acute PE.

et al. performed a retrospective analysis, evaluating patient-centered

Perhaps a so-called “hemostatic PERT” may be of equipoise while

outcomes and cost effectiveness of PERTs in 554 patients, focusing

investigating such catastrophic complications; equally important are

on 6-month survival, hospital length of stay, hospital-related costs,

objective evaluations, quality metrics, descriptive data, and research

30-day readmission rates, and in-hospital bleeding rates; all-cause

to describe the performance on how efficient and productive PERTs

mortality was significantly and consistently decreased after the in-

can be while risk-stratifying and predicting early major bleeding

ception of a designated PERT, without incurring additional hospital

events in-hospital. Thus, PERTs can offer valuable clinical implica-

costs or protracting length of stay. Moreover, there was no signifi-

tions while reaching consensus on which therapeutic strategy may

cant rise in in-hospital bleeding events.35 PERTs improved patient

be best for a given complex acute PE patient. Given the complex-

outcomes compared to patients who did not receive PERT activation

ity of post-acute PE syndrome, PERT multidisciplinary clinics may

during the same period.

35

be needed to perform continuity of care in the outpatient setting,
and to monitor and manage these patients, particularly the subset of

7 | FU T U R E PE R S PEC TI V E S A N D
CO N C LU S I O N S

patients at high risk for the development of chronic thromboembolic
disease and/or chronic thromboembolic pulmonary hypertension. 26
However, this is still an unmet goal for PERTs, but at the same time, a
potential area of interest that requires further exploratory research.

PERTs may elevate the care of patients with PE and have demon-

The PERT process is currently changing our clinical practice.

strated improvement in quality metrics such as reductions in time

More education and awareness are essential for rapid acceptance

|
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and adoption worldwide. Despite the challenging of designing and
performing a prospective randomized clinical trial evaluating the
benefits/risks of interventions executed by PERTs, we believe PERTs

8.

will continue to change the paradigm in the care of acute PE, achieving excellence in such care, with full adoption by clinical-practice
guidelines globally.

9.
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